Bridgewell

Bridgewell Biopharmaceutical is a clinical-stage biotechnology company based in Taiwan that specializes in the development of innovative drug delivery systems for oncology and central nervous system (CNS) disorders. The company's core expertise lies in its proprietary liposomal and nanoparticle platforms, which are designed to enhance the therapeutic index of established drugs by improving their pharmacokinetic profiles and ability to penetrate the blood-brain barrier. Bridgewell's lead clinical program, BWB-201, is a liposomal formulation currently in Phase 2 development for glioblastoma multiforme. Additionally, the company is advancing BWB-101 for pancreatic cancer and several pre-clinical candidates for neurodegenerative diseases like Alzheimer's and Parkinson's. Through its focus on precision delivery, Bridgewell aims to address significant unmet needs in the treatment of aggressive cancers and brain-related pathologies.